Pyxis Oncology Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.
Current Price
$2.74
+21.24%Profile
Valuation (TTM)
Market Cap$170.60M
P/E-2.14
EV—
P/B3.19
Shares Out62.26M
P/Sales12.31
Revenue$13.86M
EV/EBITDA—
Pyxis Oncology Inc (PYXS) Stock Analysis
Market Cap$170.60M
Current Price$2.74
P/E Ratio-2.14
Forward P/E—
PEG Ratio0.04
EPS$-1.28
Book Value$0.86
P/B Ratio3.19
PYXS Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 2M
Revenue
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
16M
FY24
14M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
PYXS 52-Week Range
$1.04
$5.34
50-Day MA: $1.62200-Day MA: $2.19
Did you know?
Price sits at 40% of its 52-week range.
Pyxis Oncology Inc (PYXS) Financial Summary
Pyxis Oncology Inc (PYXS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $2.74 with a market capitalization of $170.60M.
Key valuation metrics include a P/E ratio of -2.14, price-to-book ratio of 3.19, and EPS of $-1.28. The company reports a profit margin of -574.5% and return on equity of -149.1%.
PYXS Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $170.60M |
| P/E Ratio | -2.14 |
| EPS | $-1.28 |
| P/B Ratio | 3.19 |
| P/S Ratio | 12.31 |
| Profit Margin | -574.5% |
| Return on Equity | -149.1% |
| Debt/Equity | 0.35 |
PYXS Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $0.00 | $-2.77M |
| FY20 | $0.00 | $-12.83M |
| FY21 | $0.00 | $-75.97M |
| FY22 | $0.00 | $-120.72M |
| FY23 | $0.00 | $-73.79M |
| FY24 | $16.15M | $-77.33M |
| FY25 | $13.86M | $-79.62M |
PYXS Quality Indicators
Pyxis Oncology Inc maintains a profit margin of -574.5% and an operating margin of -609.2%. Return on equity stands at -149.1%. The current ratio is 3.41. Debt-to-equity ratio is 0.35.
About Pyxis Oncology Inc
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.
PYXS Free Cash Flow
Pyxis Oncology Inc generated $-63.51M in trailing twelve-month free cash flow, representing an FCF yield of -37.23%. This low FCF yield may reflect heavy reinvestment or growth spending.
PYXS Shares Outstanding
Pyxis Oncology Inc has 0.06 billion shares outstanding at a share price of $2.74, giving it a market capitalization of $170.60M.